Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Creatine for treating muscle disorders.

R A Kley1, M Vorgerd, M A Tarnopolsky

  • 1Kliniken Bergmannsheil, Ruhr University Bochum, Department of Neurology, Buerkle-de-la-Camp-Platz 1, Bochum, Germany, 44789. rudolf.a.kley@ruhr-uni-bochum.de

The Cochrane Database of Systematic Reviews
|January 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of two induced pluripotent stem cell lines (HIMRi006-A and HIMRi007-A) from Pompe patients with infantile and late disease onset.

Stem cell research·2024
Same author

Generation of two hiPSCs lines of two patients carrying truncating mutations in the dimerization domain of filamin C.

Stem cell research·2024
Same author

Generation of two human iPSC lines (HIMRi002-A and HIMRi003-A) derived from Caveolinopathy patients with rippling muscle disease.

Stem cell research·2023
Same author

Generation of a human iPSC line (HIMRi001-A) from a patient with filaminopathy.

Stem cell research·2023
Same author

Diffusion Tensor Imaging Shows Differences Between Myotonic Dystrophy Type 1 and Type 2.

Journal of neuromuscular diseases·2021
Same author

Muscle diffusion tensor imaging in glycogen storage disease V (McArdle disease).

European radiology·2018
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Creatine supplementation significantly improved muscle strength in muscular dystrophies but not metabolic myopathies. This nutritional supplement was well-tolerated, with high doses causing muscle pain in glycogenosis type V.

Area of Science:

  • Neurology
  • Nutritional Science
  • Clinical Trials

Background:

  • Hereditary muscle diseases cause progressive muscle weakness.
  • Creatine, a popular supplement, enhances muscle performance in healthy individuals.
  • Creatine may offer therapeutic benefits for myopathies.

Purpose of the Study:

  • To evaluate the efficacy of oral creatine supplementation in patients with hereditary muscle diseases.
  • To assess the impact of creatine on muscle strength and other relevant parameters.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) and quasi-RCTs.
  • Searched multiple databases (Cochrane, MEDLINE, EMBASE) and contacted experts.
  • Included participants of all ages with hereditary muscle disease receiving creatine at ≥0.03 g/kg/day.

Related Experiment Videos

Main Results:

  • Twelve trials with 266 participants were included.
  • Creatine significantly increased maximum voluntary contraction (8.47%) and lean body mass (0.63 kg) in muscular dystrophies.
  • No significant strength improvement was observed in metabolic myopathies; high-dose creatine increased muscle pain in glycogen storage disease type V.

Conclusions:

  • Short- to medium-term creatine treatment improves muscle strength and is well-tolerated in muscular dystrophies.
  • Creatine does not significantly improve muscle strength in metabolic myopathies.
  • High-dose creatine may increase muscle pain in specific conditions like glycogenosis type V.